Novartis has entered into an agreement to acquire Excellergy Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody in Phase 1. Under the terms of the agreement, Novartis will pay up to $2 billion in upfront and milestone payments to acquire Excellergy. The transaction is expected to close in H2 2026, subject to the satisfaction or waiver of customary cl...